FDA Issues Draft Guidance on Bioequivalence Studies Specifically for ANDAs
The U.S. Food and Drug Administration (FDA) on December 4, 2013 issued new draft guidance on bioequivalence studies for drugs submitted under an Abbreviated New Drug Application (ANDA). In light of the relatively few substantive changes from previous guidance, the main purpose in issuing the new draft appears to be the separation of such guidance…